Alburx Purple Book BLA 102366

BLA number
102366
Proprietary names
Alburx
Proper names
Albumin (Human)
Applicant
CSL Behring AG
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001AlburxAlbumin (Human)351(a)25G/100mLInjectionIntravenousSingle-Dose VialRxLicensed1976-07-23
002AlburxAlbumin (Human)351(a)25G/500MLInjectionIntravenousSingle-Dose VialRxLicensed1976-07-23
003AlburxAlbumin (Human)351(a)12.5G/50MLInjectionIntravenousSingle-Dose VialRxLicensed1976-07-23
004AlburxAlbumin (Human)351(a)12.5G/250MLInjectionIntravenousSingle-Dose VialRxLicensed1976-07-23

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2022-08-01U001Alburx351(a)RxCSL Behring AG
2022-08-01U002Alburx351(a)RxCSL Behring AG
2022-08-01N003Alburx351(a)RxCSL Behring AG
2022-08-01N004Alburx351(a)RxCSL Behring AG
2021-05-01U001Alburx351(a)RxCSL Behring AG
2021-05-01U002Alburx351(a)RxCSL Behring AG
2020-08-01R001Alburx351(a)RxCSL Behring AG
2020-08-01R002Alburx351(a)RxCSL Behring AG

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2022-08-01003Alburx351(a)RxLicensed1976-07-23
2022-08-01004Alburx351(a)RxLicensed1976-07-23
2020-08-01001Alburx351(a)RxLicensed1976-07-23
2020-08-01002Alburx351(a)RxLicensed1976-07-23